Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

20146,709 citationsJournal Articlebronze Open Access

Authors

John J.V. McMurray

Milton Packer · The University of Texas Southwestern Medical Center

Akshay S. Desai · Brigham and Women's Hospital

Jianjian Gong

Martin Lefkowitz

Adel R. Rizkala

Jean L. Rouleau · Montreal Heart Institute

Victor Shi

Scott D. Solomon · Brigham and Women's Hospital

Abstract

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).

Topics & Keywords

Heart Failure Treatment and Management Electrolyte and hormonal disorders Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 11, pp. 993-1004

DOI: 10.1056/nejmoa1409077

Field-Weighted Citation Impact: 242.57